Ovarian carcinosarcoma composed of high-grade carcinoma and sarcoma is an extremely rare neoplasm and typically occurs in postmenopausal women aged over 60 years. A 73-year-old female, gravida three para three, presented to our hospital with right lower abdominal pain. Right pelvic solid tumor with ascites was detected on pelvic ultrasound examination. She underwent hysterectomy, bilateral salpingo-oophorectomy and partial omentectomy, but the tumor had invaded to the right ureter, and some fragile tumor could not be taken (sub-optimal surgery). On the imprint and ascitic cytology specimens during operation, atypical cells suggestive of adenocarcinoma and spindle atypical cells with immunocytochemically vimentin positive were found. The resected tumor was histopathologically carcinosarcoma consisted of serous adenocarcinoma, chondrosarcoma and fibrosarcoma. Immunohistochemical analysis revealed that adenocarcinoma cells were positive for AE1/AE3 and fibrosarcoma cells stained with vimentin. The final diagnosis was the right ovarian carcinosarcoma (stage pT3CNxMx). Microsatellite instability was stable and BRCA1/2 mutations could not be found in the carcinosarcoma cells. The patient was given four cycles of chemotherapy with paclitaxel, carboplatin and bevacizumab regimen, and thereafter she was treated with the ifosfamide and cisplatin because of slight elevation of serum CA125.
References
[1]
Berton-Rigaud, D., Devouassoux-Shisheboran, M., Ledermann, J.A., Leitao, M.M., Powell, M.A., Poveda, A., Beale, P., Glasspool, R.M., Creutzberg, C.L., Harter, P., Kim, J.W., Reed, N.S. and Ray-Coquard, I. (2014) Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. International Journal of Gynecological Cancer, 24, S55-S60. https://doi.org/10.1097/IGC.0000000000000228
[2]
Ariyoshi, K., Kawauchi, S., Kaku, T., Nakano, H. and Tsuneyoshi, M. (2000) Prognostic Factors in Ovarian Carcinosarcoma: A Clinicopathological and Immunohistochemical Analysis of 23 Cases. Histopathology, 37, 427-436. https://doi.org/10.1046/j.1365-2559.2000.01015.x
[3]
Rauh-Hain, J.A., Birrer, M. and Del Carmen, M.G. (2016) Carcinosarcoma of the Ovary, Fallopian Tube, and Peritoneum: Prognostic Factors and Treatment Modalities. Gynecologic Oncology, 142, 248-254. https://doi.org/10.1016/j.ygyno.2016.06.003
[4]
Liu, F.S., Kohler, M.F., Marks, J.R., Bast Jr., R.C., Boyd, J. and Berchuck, A. (1994) Mutation and Overexpression of the p53 Tumor Suppressor Gene Frequently Occurs in Uterine and Ovarian Sarcomas. Obstetrics & Gynecology, 83, 118-124.
[5]
Zorzou, M.P., Markaki, S., Rodolakis, A., Kastritis, E., Bozas, G., Dimopoulos, M.A. and Papadimitriou, C.A. (2005) Clinicopathological Features of Ovarian Carcinosarcomas: A Single Institution Experience. Gynecologic Oncology, 96, 136-142. https://doi.org/10.1016/j.ygyno.2004.09.051
[6]
Paulsson, G., Andersson, S. and Sorbe, B. (2013) A Population-Based Series of Ovarian Carcinosarcomas with Long-Term Follow-Up. Anticancer Research, 33, 1003-1008.
[7]
Buhard, O., Cattaneo, F., Wong, Y.F., Yim, S.F., Friedman, E., Flejou, J.F., Duval, A. and Hamelin, R. (2006) Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors. Journal of Clinical Oncology, 24, 241-251. https://doi.org/10.1200/JCO.2005.02.7227
[8]
Baretta, Z., Mocellin, S., Goldin, E., Olopade, O.I. and Huo, D. (2016) Effect of BRCA Germline Mutations on Breast Cancer Prognosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 95, e4975. https://doi.org/10.1097/MD.0000000000004975
[9]
Guo, N. and Peng, Z. (2017) Does Serum CA125 Have Clinical Value for Follow-Up Monitoring of Postoperative Patients with Epithelial Ovarian Cancer? Results of a 12-Year Study. Journal of Ovarian Research, 10, 14. https://doi.org/10.1186/s13048-017-0310-y
[10]
Brackmann, M., Stasenko, M., Uppal, S., Erba, J., Reynolds, R.K. and McLean, K. (2018) Comparison of First-Line Chemotherapy Regimens for Ovarian Carcinosarcoma: A Single Institution Case Series and Review of the Literature. BMC Cancer, 18, 172. https://doi.org/10.1186/s12885-018-4082-6
[11]
Rutledge, T.L., Gold, M.A., McMeekin, D.S., Huh, W.K., Powell, M.A., Lewin, S.N., Mutch, D.G., Johnson, G.A., Walker, J.L. and Mannel, R.S. (2006) Carcinosarcoma of the Ovary—A Case Series. Gynecologic Oncology, 100, 128-132. https://doi.org/10.1016/j.ygyno.2005.07.119
[12]
del Carmen, M.G., Birrer, M. and Schorge, J.O. (2012) Carcinosarcoma of the Ovary: A Review of the Literature. Gynecologic Oncology, 125, 271-277. https://doi.org/10.1016/j.ygyno.2011.12.418
[13]
Menon, S., Deodhar, K., Rekhi, B., Dhake, R., Gupta, S., Ghosh, J., Maheshwari, A., Mahantshetty, U., Shrivastva, S., Budukh, A., Tongaonkar, H.B. and Kerkar, R. (2013) Clinico-Pathological Spectrum of Primary Ovarian Malignant Mixed Mullerian Tumors (OMMMT) from a Tertiary Cancer Institute: A Series of 27 Cases. Indian Journal of Pathology & Microbiology, 56, 365-371. https://doi.org/10.4103/0377-4929.125293
[14]
Kamii, M., Kuroda, H., Suzuki, K. and Isonishi, S. (2018) Usefulness of Ascites Cytology for the Evaluation of Chemotherapy Response in Ovarian Carcinosarcoma. Cytopathology, 29, 306-308. https://doi.org/10.1111/cyt.12527
[15]
Ikeda, K., Tate, G., Suzuki, T. and Mitsuya, T. (2005) Effusion Cytodiagnosis of Carcinosarcoma Derived from the Female Genital Tract: Immunohistochemical Features of MMP-7 and Ki-67 and Immunofluorescence Double Staining Analyses of Eight Cases. Gynecologic Oncology, 97, 323-329. https://doi.org/10.1016/j.ygyno.2004.12.024
[16]
Kanbour, A.I., Buchsbaum, H.J., Hall, A. and Kanbour, A.I. (1989) Peritoneal Cytology in Malignant Mixed Mullerian Tumors of the Uterus. Gynecologic Oncology, 33, 91-95. https://doi.org/10.1016/0090-8258(89)90610-0
[17]
Cantrell, L.A. and Van Le, L. (2009) Carcinosarcoma of the Ovary a Review. Obstetrical & Gynecological Survey, 64, 673-680. https://doi.org/10.1097/OGX.0b013e3181b8aff3
[18]
Sreenan, J.J. and Hart, W.R. (1995) Carcinosarcomas of the Female Genital Tract. A Pathologic Study of 29 Metastatic Tumors: Further Evidence for the Dominant Role of the Epithelial Component and the Conversion Theory of Histogenesis. The American Journal of Surgical Pathology, 19, 666-674. https://doi.org/10.1097/00000478-199506000-00007
[19]
Fujii, H., Yoshida, M., Gong, Z.X., Matsumoto, T., Hamano, Y., Fukunaga, M., Hruban, R.H., Gabrielson, E. and Shirai, T. (2000) Frequent Genetic Heterogeneity in the Clonal Evolution of Gynecological Carcinosarcoma and Its Influence on Phenotypic Diversity. Cancer Research, 60, 114-120.
[20]
Gorai, I., Yanagibashi, T., Taki, A., Udagawa, K., Miyagi, E., Nakazawa, T., Hirahara, F., Nagashima, Y. and Minaguchi, H. (1997) Uterine Carcinosarcoma Is Derived from a Single Stem Cell: An in Vitro Study. International Journal of Cancer, 72, 821-827. https://doi.org/10.1002/(SICI)1097-0215(19970904)72:5<821::AID-IJC19>3.0.CO;2-B
[21]
Boussios, S., Karathanasi, A., Zakynthinakis-Kyriakou, N., Tsiouris, A.K., Chatziantoniou, A.A., Kanellos, F.S. and Tatsi, K. (2019) Ovarian Carcinosarcoma: Current Developments and Future Perspectives. Critical Reviews in Oncology/Hematology, 134, 46-55. https://doi.org/10.1016/j.critrevonc.2018.12.006
[22]
Gotoh, O., Sugiyama, Y., Takazawa, Y., Kato, K., Tanaka, N., Omatsu, K., Takeshima, N., Nomura, H., Hasegawa, K., Fujiwara, K., Taki, M., Matsumura, N., Noda, T. and Mori, S. (2019) Clinically Relevant Molecular Subtypes and Genomic Alteration-Independent Differentiation in Gynecologic Carcinosarcoma. Nature Communications, 10, 4965. https://doi.org/10.1038/s41467-019-12985-x
[23]
Amant, F., Vloeberghs, V., Woestenborghs, H., Moerman, P. and Vergote, I. (2003) Transition of Epithelial toward Mesenchymal Differentiation during Ovarian Carcinosarcoma Tumorigenesis. Gynecologic Oncology, 90, 372-377. https://doi.org/10.1016/S0090-8258(03)00326-3
[24]
Sonoda, Y., Saigo, P.E., Federici, M.G. and Boyd, J. (2000) Carcinosarcoma of the Ovary in a Patient with a Germline BRCA2 Mutation: Evidence for Monoclonal Origin. Gynecologic Oncology, 76, 226-229. https://doi.org/10.1006/gyno.1999.5681
[25]
D’Andrea, A.D. (2018) Mechanisms of PARP Inhibitor Sensitivity and Resistance. DNA Repair (Amst), 71, 172-176. https://doi.org/10.1016/j.dnarep.2018.08.021
